Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 3
2013 7
2014 3
2015 8
2016 12
2017 21
2018 17
2019 20
2020 28
2021 18
2022 16
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31344348

135 results

Results by year

Filters applied: . Clear all
Page 1
Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
Jiménez-Vacas JM, Herrero-Aguayo V, Gómez-Gómez E, León-González AJ, Sáez-Martínez P, Alors-Pérez E, Fuentes-Fayos AC, Martínez-López A, Sánchez-Sánchez R, González-Serrano T, López-Ruiz DJ, Requena-Tapia MJ, Castaño JP, Gahete MD, Luque RM. Jiménez-Vacas JM, et al. Transl Res. 2019 Oct;212:89-103. doi: 10.1016/j.trsl.2019.07.001. Epub 2019 Jul 9. Transl Res. 2019. PMID: 31344348
Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma.
López-Cánovas JL, Del Rio-Moreno M, García-Fernandez H, Jiménez-Vacas JM, Moreno-Montilla MT, Sánchez-Frias ME, Amado V, L-López F, Fondevila MF, Ciria R, Gómez-Luque I, Briceño J, Nogueiras R, de la Mata M, Castaño JP, Rodriguez-Perálvarez M, Luque RM, Gahete MD. López-Cánovas JL, et al. Cancer Lett. 2021 Jan 1;496:72-83. doi: 10.1016/j.canlet.2020.10.010. Epub 2020 Oct 8. Cancer Lett. 2021. PMID: 33038489
SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.
Fuentes-Fayos AC, Pérez-Gómez JM, G-García ME, Jiménez-Vacas JM, Blanco-Acevedo C, Sánchez-Sánchez R, Solivera J, Breunig JJ, Gahete MD, Castaño JP, Luque RM. Fuentes-Fayos AC, et al. J Exp Clin Cancer Res. 2022 Jan 27;41(1):39. doi: 10.1186/s13046-022-02241-4. J Exp Clin Cancer Res. 2022. PMID: 35086552 Free PMC article.
Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
Jiménez-Vacas JM, Herrero-Aguayo V, Montero-Hidalgo AJ, Gómez-Gómez E, Fuentes-Fayos AC, León-González AJ, Sáez-Martínez P, Alors-Pérez E, Pedraza-Arévalo S, González-Serrano T, Reyes O, Martínez-López A, Sánchez-Sánchez R, Ventura S, Yubero-Serrano EM, Requena-Tapia MJ, Castaño JP, Gahete MD, Luque RM. Jiménez-Vacas JM, et al. EBioMedicine. 2020 Jan;51:102547. doi: 10.1016/j.ebiom.2019.11.008. Epub 2020 Jan 3. EBioMedicine. 2020. PMID: 31902674 Free PMC article.
Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
Alors-Perez E, Blázquez-Encinas R, Alcalá S, Viyuela-García C, Pedraza-Arevalo S, Herrero-Aguayo V, Jiménez-Vacas JM, Mafficini A, Sánchez-Frías ME, Cano MT, Abollo-Jiménez F, Marín-Sanz JA, Cabezas-Sainz P, Lawlor RT, Luchini C, Sánchez L, Sánchez-Hidalgo JM, Ventura S, Martin-Hijano L, Gahete MD, Scarpa A, Arjona-Sánchez Á, Ibáñez-Costa A, Sainz B Jr, Luque RM, Castaño JP. Alors-Perez E, et al. J Exp Clin Cancer Res. 2021 Dec 2;40(1):382. doi: 10.1186/s13046-021-02153-9. J Exp Clin Cancer Res. 2021. PMID: 34857016 Free PMC article.
The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
Hormaechea-Agulla D, Gahete MD, Jiménez-Vacas JM, Gómez-Gómez E, Ibáñez-Costa A, L-López F, Rivero-Cortés E, Sarmento-Cabral A, Valero-Rosa J, Carrasco-Valiente J, Sánchez-Sánchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castaño JP, Luque RM. Hormaechea-Agulla D, et al. Mol Cancer. 2017 Aug 29;16(1):146. doi: 10.1186/s12943-017-0713-9. Mol Cancer. 2017. PMID: 28851363 Free PMC article.
Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R, Wojtuszkiewicz A, El Hassouni B, Funel N, Gandellini P, Lagerweij T, Buonamici S, Blijlevens M, Zeeuw van der Laan EA, Zaffaroni N, Deraco M, Kusamura S, Würdinger T, Peters GJ, Molthoff CFM, Jansen G, Kaspers GJL, Cloos J, Giovannetti E. Sciarrillo R, et al. EBioMedicine. 2019 Jan;39:215-225. doi: 10.1016/j.ebiom.2018.12.025. Epub 2018 Dec 20. EBioMedicine. 2019. PMID: 30581150 Free PMC article.
135 results